PeptidePedia
Experimental

Semax

A Russian-developed ACTH(4-10) analog used intranasally and studied for cognitive performance and stroke recovery.

In plain English

Semax is a heptapeptide developed in Russia as a synthetic analog of the ACTH(4-10) fragment. It is administered intranasally and has been studied in Russian clinical practice for cognitive enhancement, stroke recovery, and optic-nerve disorders. The mainstream Western evidence base is small. People commonly research Semax for focus, attention, and post-stroke recovery. It is not FDA-approved.

What it is

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment, lacking the corticotropic activity of full-length ACTH.

Mechanism (summary)

Proposed mechanisms include modulation of BDNF and nerve growth factor, neuroprotective effects in ischemic injury, and influence on the dopaminergic system.

Why people research it

  • Cognitive function and attention
  • Ischemic stroke recovery
  • Optic nerve injury
  • ADHD-spectrum symptoms

Human evidence

Russian clinical trials describe benefits in acute stroke recovery and cognitive complaints. Mainstream English-language replication is limited.

Animal / lab evidence

Rodent studies show neuroprotective effects in ischemia models and modulation of growth factors and dopamine.

Key studies

Each summary explains the design, what was found, and what it doesn't prove.

Human RCT2008·Adults with acute ischemic stroke
Semax in acute ischemic stroke: a Russian multicenter clinical trial

In Russian stroke trials, Semax was linked to better neurological recovery scores than standard care alone.

Finding: Semax was associated with improved neurological recovery scores compared with standard care.
Limitations: Open-label aspects, methodologic constraints; results not widely replicated in Western trials.
Review2007·Animal and human review
Semax effects on cognitive performance: review

A review of how Semax has been studied for memory and attention in animals and small human groups.

Finding: Reviews data describing improvements in attention, memory, and cognitive performance in animals and small human cohorts.
Limitations: Review article.

History

Developed at the Institute of Molecular Genetics, Russian Academy of Sciences. Registered in Russia in 2000.

Important:

PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.

Related peptides